Standard therapy for INCS clinical trials

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

This study looks at a new medicine called lebrikizumab for people with chronic rhinosinusitis and nasal polyps, who are already using nasal sprays. It aims to see how well it works and if it's safe over about 18 months.